NCT05319028View on ClinicalTrials.gov

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 23, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Non-GCB/ABC Diffuse Large B-Cell LymphomaWith and Without MyD88 and/or CD79B Mutations
Interventions
DRUG

Mivavotinib

oral tablet

Trial Locations (7)

19104

University of Pennsylvania, Philadelphia

43623

Toledo Clinic Cancer Center, Toledo

44106

University Hospitals Cleveland Medical Center, Cleveland

48202

Henry Ford Health, Detroit

60208

Northwestern University, Evanston

77030

The University of Texas, M. D. Anderson Cancer Center, Houston

78229

The University of Texas Health Science Center at San Antonio, San Antonio

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY